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Dexmedetomidine is a highly selective agonist of 𝛼2-receptors with sedative, anxiolytic, analgesic, and anesthetic properties.
Neuroprotective effects of dexmedetomidine have been reported in various brain injurymodels. In the present study,we investigated
the effects of dexmedetomidine on neurodegeneration, oxidative stress markers, and inflammation following the induction of
hyperoxia in neonatal rats. Six-day-old Wistar rats received different concentrations of dexmedetomidine (1, 5, or 10𝜇g/kg
bodyweight) and were exposed to 80% oxygen for 24 h. Sex-matched littermates kept in room air and injected with normal saline or
dexmedetomidine served as controls. Dexmedetomidine pretreatment significantly reduced hyperoxia-induced neurodegeneration
in different brain regions of the neonatal rat. In addition, dexmedetomidine restored the reduced/oxidized glutathione ratio and
attenuated the levels of malondialdehyde, a marker of lipid peroxidation, after exposure to high oxygen concentration. Moreover,
administration of dexmedetomidine induced downregulation of IL-1𝛽 on mRNA and protein level in the developing rat brain.
Dexmedetomidine provides protections against toxic oxygen induced neonatal brain injury which is likely associated with oxidative
stress signaling and inflammatory cytokines. Our results suggest that dexmedetomidine may have a therapeutic potential since
oxygen administration to neonates is sometimes inevitable.
1. Introduction
Premature birth is the leading cause of child mortality and
morbidity in preterm infants because most organs and also
the antioxidant enzyme system are not fully developed struc-
turally and functionally [1, 2]. Despite advances in perinatal
medicine, whereby the chances of survival of premature
infants could be significantly increased, in preterm infants
with low birth weight impairment of brain development is
often observed [3, 4].
A general anesthesia is sometimes essential for premature
infants with medical indication. In pediatric anesthesia usu-
ally the same anesthetics and adjuvants are used as in adults.
NMDA antagonists like ketamine and/or GABAA receptor
agonists, such as benzodiazepines, barbiturates, isoflurane, or
propofol, are employed [5, 6]. In particular, premature and
newborn infants demonstrate a significantly higher risk of
anesthesia [7] and perioperative morbidity and mortality is
increased due to the immature organ systems [8]. In addition
to required medical interventions under sedation also high
oxygen concentrations are a major problem. In recent years,
experimental studies and clinical observations showed that
oxygen, which is widely used in neonatal intensive care for
treatment of respiratory distress, triggers a disruption of
intracellular redox homeostasis and disturbed neurological
development of preterm infants [9–11]. As we demonstrated
recently in experimental models, this disturbance can induce
oxidative stress by modulation of the glutathione ratio and
an increasing lipid peroxidation [12–15], inflammation by
increased levels of proinflammatory cytokines [13, 15, 16],
leading to increased neurodegeneration [12, 16, 17], and
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inhibition of neuronal maturation [17, 18] in the developing
brain.
Dexmedetomidine is a potent and highly selective agonist
of 𝛼2-receptors with sedative, anxiolytic, analgesic, and anes-
thetic properties [19–21]. In addition, it is generally reported
that dexmedetomidine has neuroprotective effects in differ-
ent animal models [22–27] and minimal side effects on the
respiratory tract and the gastrointestinal function that min-
imizes the exposure to other narcotics and benzodiazepines
[23, 28–30]. Recent studies suggest the 𝛼2-adrenoceptor ago-
nist dexmedetomidine to attenuate anesthetic agent induced
neuroapoptosis [26, 31, 32] and it appears for long term
sedation as an alternative tomidazolam and propofol [33, 34].
Advantages of dexmedetomidine are shorter ventilation and
recovery times and lower hypertension and tachycardia. In
particular, the shortening of the duration of ventilation seems
to be relevant in connection with the higher oxygen toxicity
by prolonged ventilation and the associated development of
chronic lung disease and the consequent motor and cognitive
deficits in preterm born infants. First results of clinical trials
in preterm infants revealed a decrease in the duration of
mechanical ventilation by half and no need for additional
sedative administration [35, 36].
The aim of this study was to investigate the effect of dif-
ferent concentrations of dexmedetomidine to the immature
brain in a neonatal rat model of oxygen toxicity on neurode-
generation, oxidative stressmarkers, and the expression of the
proinflammatory cytokine IL-1𝛽.
2. Materials and Methods
2.1. Animals and Drug Administration. All procedures were
approved by the State Animal Welfare Authorities (LAGeSo
G0145/13) and followed institutional guidelines. Six-day-
old Wistar rats from time-pregnant mothers were obtained
from Charite´-Universita¨tsmedizin Berlin (Germany) and
randomly assigned to cages and treatment.
Dexmedetomidine (DEX; dexdor, Orion Pharma, Espoo,
Finland) was dissolved in phosphate buffered saline. Three
doses of the drug (1, 5, and 10 𝜇g/kg body weight) were
used and all injections were given intraperitoneally (i.p.)
as a fixed proportion of body weight (100 𝜇L/10 g). The rat
pups are divided into different biological groups (description
with the relevant experimental abbreviations): (1) control
group (CON; 21% O
2
, room air) with 0,9% saline, (2) verum
group (21% O
2
) with 1 𝜇g/kg DEX (DEX1), (3) verum group
with 5 𝜇g/kg DEX (DEX5), (4) verum group with 10 𝜇g/kg
DEX (DEX10), (5) hyperoxia group (HY; 80% O
2
, OxyCycler
BioSpherix, Lacona, NY) with 0,9% saline, (6) hyperoxia
with 1 𝜇g/kg DEX (HYDEX1), (7) hyperoxia with 5𝜇g/kg
DEX (HYDEX5), and (8) hyperoxia with 10 𝜇g/kg DEX
(HYDEX10), each with a number of six animals per group
and different gender. For hyperoxia or normoxia exposure,
pups were kept together with their dams. Saline or DEX
was administrated once 15min before the start of oxygen
exposure.
2.2. Tissue Preparation. At 24 h of exposure the animals were
anaesthetized with an i.p. injection of ketamine (50mg/kg),
xylazine (10mg/kg), and acepromazine (2mg/kg) 5min
before being perfused. For molecular analysis, pups were
transcardially perfused with normal saline (pH 7.4) and then
decapitated, the olfactory bulb and cerebellumwere removed,
and brain hemispheres were snap-frozen in liquid nitrogen
and stored at −80∘C. For immunohistochemical analysis,
animals were perfused with PBS followed by perfusion with
4% paraformaldehyde at pH 7.4 and the brains were postfixed
at 4∘C for 3 days, embedded in paraffin, and processed for
histological staining.
2.3. DNA Fragmentation Assay. Paraffin-embedded sections
were cut (5 𝜇m), deparaffinized in Roti-Histol (Carl Roth,
Karlsruhe, Germany) twice for 10min each, rehydrated in
descending ethanol series, and rinsed in phosphate buffered
saline for 3min each at room temperature. After deparaf-
finization of sections an in situ detection of cells with
DNA-strand breaks was performed by the TUNEL labeling
method using a TdT-FragEL DNA fragmentation detection
kit (Millipore, Darmstadt, Germany) according to the manu-
facturer’s instructions. Negative controls were performed by
substituting Tris-buffered saline for the TdT enzyme.
The TUNEL positive cells were analyzed in frontal cor-
tex (FC), retrosplenial cortex (RSC), hypothalamus (HTH),
thalamus (TH), and the hippocampus. Sections were viewed
by light microscopy while blinded using a LEICA DM 2000
microscope equipped with a 200x magnification. TUNEL
positive cells were counted in the anatomical regions of the
brain in up to twelve different sections per animal and region.
2.4. Determination of Total Glutathione (GSH and GSSG).
Total glutathione (GSH and GSSG) was measured in brain
homogenates using the thiol reagent 5,5󸀠-dithiobis-2-nitrob-
enzoic acid (DTNB) as shown previously [14]. In brief, for the
determination of reduced glutathione (GSH) and oxidized
glutathione (GSSG), the brains were homogenized and the
homogenates were treated with a mixture of metaphosphoric
acid, EDTA, and NaCl. After centrifugation, aliquots were
taken for neutralization with disodium hydrogen phosphate
followed by addition of DTNB. GSH was determined after
reaction with DTNB in a spectrophotometer at 412 nm.
For the determination of GSSG 4-vinylpyridine was added
and then incubated for 1 hour at room temperature. 4-
Vinylpyridine is able to mask the GSH content without
interfering with the spectrophotometrical determination of
GSSG at 412 nm. GSH and GSSG levels are reported as
nmol/mg protein.
2.5. Measurement of Lipid Peroxidation. Lipid peroxidation
was determined by the reaction of thiobarbituric acid with
malondialdehyde (MDA), a product of lipid breakdown
caused by oxidative stress as previously described [14].
A SUPELCOSIL LC-18-DB HPLC reversed-phase column
(Sigma-Aldrich, Munich, Germany; 5𝜇m particle size, 250
× 10mm I.D.) was utilized for the detection of MDA levels
in brain homogenates. The MDA level was determined by
fluorescence (525/550 nm) with a 50mM potassium phos-
phate buffer (pH 6.8) and 40% methanol mobile phase at
1.5mL/min flow rate.
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2.6. RNA Extraction and Semiquantitative Real-Time PCR.
Total RNA was isolated from snap-frozen tissue by acidic
phenol/chloroform extraction (peqGOLD RNAPure;
PEQLAB Biotechnologie, Erlangen, Germany) and 2 𝜇g of
RNA was reverse-transcribed. The PCR products of IL-1𝛽
and hypoxanthine-guanine phosphoribosyltransferase (HPRT,
as internal standard) were quantified in real time, using
dye-labeled fluorogenic reporter oligonucleotide probes
and primers (Metabion, Munich, Germany) with the fol-
lowing sequences and corresponding GenBank accession
numbers: IL-1𝛽 (NM 031512) sense 5󸀠-AACAAAAAT-
GCCTCGTGCTGTCT-3󸀠, antisense 5󸀠-TGTTGGCTTATG-
TTGTGTCCATTG-3󸀠, probe 5󸀠-ACCCATGTGAGCTGA-
AAGCTCTCC-3󸀠; HPRT (NM 012583) sense 5󸀠-GGAAAG-
AACGTCTTGATTGTTGAA-3󸀠, antisense 5󸀠-CCAACA-
CCTTGAGAGGTCCTTTT-3󸀠, and probe 5󸀠-CTTTCC-
CTTGGTCAAGCAGTACAGCCCC-3󸀠. All probes were
labeled at their 5󸀠 ends with the reporter dye 6-carboxy-
fluoresceine (FAM) and at their 3󸀠 ends with the quencher
dye 6-carboxy-tetramethylrhodamine (TAMRA). Real-time
PCR and detection were performed in triplicate and repeated
3 times for each sample using a total reactive volume of
13 𝜇L which contained 6,5𝜇L of 2x TaqMan Universal PCR
Master Mix (Applied Biosystems, Foster City, CA, USA),
2.5 𝜇L of 1.25 𝜇M oligonucleotide mix, 0,5 𝜇L (0,5 𝜇M) of
probe, and 50 ng of cDNA template. The PCR amplification
was performed in 96-well optical reaction plates for 40
cycles with each cycle at 94∘C for 15 s and 60∘C for 1min.
The expression of IL-1𝛽 and HPRT was analyzed with the
real-time PCR ABI Prism 7500 sequence detection system
(Applied Biosystems) according to the 2−ΔΔCT method [37].
2.7. Immunoblotting. Snap-frozen brain tissue was homog-
enized in RIPA buffer solution for protein extraction. The
homogenate was centrifuged at 1,050 g (4∘C) for 10min, and
the microsomal fraction was subsequently centrifuged at
17,000 g (4∘C) for 20min. After collecting the supernatant,
protein concentrations were determined using the Pierce
BCA kit (Pierce, Rockford, IL, USA) with a 30min incuba-
tion at 37∘C prior to spectrophotometry at 562 nm. Protein
extracts (30 𝜇g per sample) were denatured in Laemmli
sample loading buffer at 95∘C, separated by 15% of sodium
dodecyl sulfate polyacrylamide gel electrophoresis, and elec-
trotransferred in transfer buffer to a nitrocellulosemembrane
(0.2 𝜇m pore, Protran; Schleicher & Schu¨ll, Dassel, Ger-
many). Nonspecific protein binding was prevented by treat-
ing the membrane with 5% nonfat dry milk in Tris-buffered
saline/0.1% Tween 20 for 1 h at room temperature. Equal
loading and transfer of proteinswas confirmedby staining the
membranes with Ponceau S solution (Fluka, Buchs, Switzer-
land). The membranes were incubated overnight at 4∘C with
rabbit polyclonal anti-IL-1𝛽 (17 kDa; 1 : 1000; PromoKine,
Heidelberg, Germany). Horseradish peroxidase-conjugated
secondary anti-rabbit antibody was diluted 1 : 2000 (Amer-
sham Biosciences, Bucks, United Kingdom). Positive signals
were visualized using the SuperSignal West Pico kit (Pierce)
according to the manufacturer’s directions and quantified
using a ChemiDoc XRS+ system and the software Image Lab
(Bio-Rad,Munich, Germany).Membranes were stripped and
then washed, blocked, and reprobed overnight at 4∘C with
mouse anti-𝛽-actin monoclonal antibody (42 kDa; 1 : 10.000;
Sigma-Aldrich). Each experiment was repeated three times.
2.8. Statistical Analyses. All data are expressed as mean ±
standard error of the mean (SEM). Groups were compared
using a one-way analysis of variance (ANOVA), and sig-
nificance was determined using Bonferroni’s correction for
multiple comparisonswith independent sample 𝑡-test. A two-
sided 𝑃 value < 0.05 was considered to be significant. All
graphics and statistical analyses were performed using the
GraphPad Prism 6.0 software (GraphPad Software, La Jolla,
CA, USA).
3. Results
3.1. Dexmedetomidine Ameliorates Hyperoxia-Induced Neu-
rodegeneration in the Infant Brain. That oxidative stress is
a trigger of cell death is well known. We have investigated
the changes in oxidative stress on the apoptotic cell death
by TUNEL assay. These investigations were carried out in
the frontal cortex (FC) and retrosplenial cortex (RSC), in
the deep graymatter (hypothalamus (HTH), thalamus (TH)),
and in the hippocampus.
In detail, exposure to 24 h of hyperoxia (HY) from P6 to
P7 resulted in a large increase of TUNEL positive cells and
the antiapoptotic ability of dexmedetomidine was able to be
detected by a significant decrease in the investigated different
concentrations (FC: HY 502.9 + 13.0% versus HYDEX1
230.7 + 19.5%, HYDEX5 155.0 + 27.2%, and HYDEX10 62.1
+ 7.2%; RSC: HY 448.3 + 25.3% versus HYDEX1 196.8 +
31.2%, HYDEX5 203.4 + 24.6%, andHYDEX10 142.2 + 25.9%;
HTH: HY 502.9 + 45.0% versus HYDEX1 142.6 + 16.9%,
HYDEX5 169.9 + 32.5%, and HYDEX10 138.7 + 16.2%; TH:
HY 442.4 + 42.3% versus HYDEX1 195.5 + 33.2%, HYDEX5
215.6 + 18.7%, and HYDEX10 197.5 + 41.9%) compared to
control animals (CON; Figures 1(a) and 1(b)). Particularly
DEX10 under hyperoxic conditions can reduce apoptotic cell
rate in the cortex and hypothalamus to control level and sig-
nificantly among them in the frontal cortex. In the thalamus,
a significant reduction by DEX under oxygen exposure was
demonstrated but did not reach the controls. DEX under
normoxic conditions showed a significant increase of TUNEL
positive cells in the cortices with DEX10 and in the thalamus
with DEX all over (Figure 1(b)). The results of the dentate
gyrus show a similar antiapoptotic effect of DEX (data not
shown). A statistical evaluation of the dentate gyrus was not
possible due to low cell counts.
3.2. Treatment with Dexmedetomidine Modifies Hyperoxia-
Affected Levels of Reduced (GSH) and Oxidized Glutathione
(GSSG) in the Developing Brain. As we showed previ-
ously, neonatal oxygen toxicity causes an imbalance of the
glutathione-redox-system correlating with an increase of
neurodegeneration in the immature brain [12–15].
Analysis of GSH and GSSG levels by reaction with
the classical thiol reagent DTNB and spectrophotometrical
measurement at 412 nmwas performed in samples from total
brain extracts of 7-day-old rats (𝑛 = 6 per group) exposed
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Figure 1: Apoptosis caused by hyperoxia is prevented by dexmedetomidine. (a) Representative TUNEL staining images (original
magnification ×400) of rat brain frontal cortices (FC), retrosplenial cortices (RSC), hypothalamus (HTH), and thalamus (TH) of P7 control
pups in room air without (CON) and with dexmedetomidine administration (DEX1, DEX5, and DEX10, corresponding to the concentrations
of 1, 5, and 10𝜇g/kg) and after 24 h of hyperoxia from P6 to P7 without (HY) andwith dexmedetomidine administration (HYDEX1, HYDEX5,
and HYDEX10). (b) Quantitation of TUNEL positive cells in the rat brain frontal cortices (FC), retrosplenial cortices (RSC), hypothalamus
(HTH), and thalamus (TH) showed that relative to the control (white bars) hyperoxia at 24 h significantly increased these cell counts in cortex
and deep grey matter (black bars). These levels were significantly decreased through systemic dexmedetomidine pretreatment (hatched grey
bars; DEX 1, 5, and 10𝜇g/kg). However, dexmedetomidine administration resulted in increased TUNEL positive cells in control rats most
profound in TH (grey bars; DEX 1, 5, and 10𝜇g/kg). Data are expressed relative to the normoxia-exposed control group (white bars, 100%).
Bars represent mean + SEM; 𝑛 = 6 per group; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001 versus normoxia/control; ##𝑃 < 0.01 and ###𝑃 < 0.001
versus hyperoxia.
to (i) normoxia and saline injections (CON), (ii) hyperoxia
and saline injections (HY), (iii) hyperoxia andDEX (HYDEX;
1, 5, or 10 𝜇g/kg), and (iv) normoxia and DEX (DEX; 1,
5, or 10 𝜇g/kg). 24 h of hyperoxia triggered the decrease
of GSH levels in brain extracts (Figure 2(a): CON: 11.42 +
0.11 nmol/mg protein and HY: 9.79 + 0.06 nmol/mg protein).
When DEX was administered together with hyperoxia, it
significantly increased the levels of GSH at a concentration of
5 and 10 𝜇g/kg DEX (HYDEX5: 10.19 + 0.06 nmol/mg protein
and HYDEX10: 11.16 + 0.09 nmol/mg protein).
Figure 2(b) shows the increased level of GSSG in the
developing brain after 24 h of hyperoxia (CON: 0.273 +
0.003 nmol/mg protein and HY: 0.046 + 0.007 nmol/mg
protein). DEX coapplication reduced the hyperoxia-induced
increase of GSSG levels significantly at 5 and 10 𝜇g/kg DEX
(HYDEX5: 0.398 + 0.008 nmol/mg protein and HYDEX10:
0.255 + 0.008 nmol/mg protein).
In total, hyperoxia triggered the decrease of the GSH/
GSSG ratio in the developing rat brain (Figure 2(c): CON:
41.94 + 0.78 and HY: 21.52 + 0.40). When DEX was adminis-
tered at the start of hyperoxia, the levels of GSH/GSSG ratio
significantly increased at 5 and 10𝜇g/kg of DEX (HYDEX5:
25.63 + 0.60 and HYDEX10: 43.95 + 1.62).
3.3. Induction of Lipid Peroxidation by Hyperoxia in the
Neonatal Brain Is Attenuated by Dexmedetomidine Treatment.
To demonstrate that the changes obtained in the level of GSH
and GSSG may be connected with an altered lipid perox-
idation, we examined immature rat brains after treatment
of hyperoxia, normoxia, dexmedetomidine, and/or normal
saline treatment for the concentration of malondialdehyde
(MDA). Increased MDA levels, as a sign of lipid breakdown,
were evident in rat brains at 24 h of hyperoxiawhen compared
to normoxic animals, whereas a single DEX administration
before beginning hyperoxia exposure reduced these levels
significantly at 5 and 10 𝜇g/kg DEX (Figure 3: CON: 5.63 +
0.14 nmol/mg protein and HY: 14.57 + 0.16 nmol/mg protein;
HYDEX5: 13.62 + 0.19 nmol/mg protein and HYDEX10:
10.18 + 0.31 nmol/mg protein).
3.4. Dexmedetomidine Treatment Reduces IL-1𝛽 Expression
underHyperoxic Conditions in the Infant Brain. Aspreviously
shown by our group hyperoxic conditions lead to an increase
in IL-1𝛽 expression in the immature brain [13, 15, 16].
Hyperoxia triggered an increase of IL-1𝛽mRNA in brain
homogenates of neonatal rats as shown by semiquantitative
real-time PCR (Figure 4(a): HY: 465.99 + 64.69%). Control





































































































































































Figure 2: Effect of dexmedetomidine on hyperoxia-modified GSH and GSSG levels in the developing brain. (a) Reduced GSH levels were
evident in total rat brain extracts 24 h after the initiation of hyperoxia (black bar) when compared to normoxic animals (white bar). These
levels were increased through dexmedetomidine (DEX) pretreatment in a concentration dependent manner (hatched grey bars: 1, 5, and
10𝜇g/kg). (b) Increased levels of oxidized GSSG were obvious in total brain extracts at 24 h of hyperoxia (black bar) when compared with
normoxic control animals (white bar).These levels were decreased through pretreatment with DEX (hatched grey bars: 1, 5, and 10𝜇g/kg). (c)
ReducedGSH/GSSG ratio levelswere evident in rat brain extracts at 24 h of hyperoxia (black bar)when compared to normoxic control animals
(white bar).These levels were upregulated throughDEX pretreatment (hatched grey bars: 1, 5, and 10𝜇g/kg). Application of dexmedetomidine
under room air (grey bars) showed no effect on GSH or GSSG levels. Bars represent mean + SEM; 𝑛 = 6 per group; ∗∗∗𝑃 < 0.001 versus
normoxia/control; ###𝑃 < 0.001 versus hyperoxia.


























































Figure 3: Alteration of lipid peroxidation by hyperoxia in the imma-
ture brain. Hyperoxia lead to a significant increase of MDA levels
after 24 h of oxygen exposure (black bar), whereas a single DEX
application of 5 or 10 𝜇g/kg (hatched grey bars) before hyperoxia
exposure reduced these levels significantly. Bars represent mean +
SEM, 𝑛 = 6 per group, ∗𝑃 < 0.05 and ∗∗∗𝑃 < 0.001 versus
normoxia/control; ##𝑃 < 0.01 and ###𝑃 < 0.001 versus hyperoxia.
animals showed low mRNA levels of IL-1𝛽 (CON: 100.36 +
11.41%). When dexmedetomidine was administered together
with hyperoxia, it significantly ameliorated the expression of
proinflammatory IL-1𝛽 depending on theDEX concentration
(HYDEX5: 310.29 + 21.77% and HYDEX10: 177.66 + 22.33%)
on mRNA levels in rat pups. Pretreatment with DEX in
animals kept under normoxic conditions had no effect on
IL-1𝛽 gene expression (DEX1: 117.18 + 11.58%, DEX5: 121.41 +
9.14%, and DEX10: 135.31 + 12.85%).
Western blotting demonstrated that protein expression of
IL-1𝛽 is significantly increased following oxygen treatment
for 24 h (Figure 4(b): HY: 336.66 + 17.25%) compared to
control animals (CON: 100.00 + 7.31%). A significant effect on
IL-1𝛽 protein levels was seen upon a single dexmedetomidine
application of 5 or 10 𝜇g/kg DEX in hyperoxia-exposed
animals (HYDEX5: 250.96 + 13.55% and HYDEX10: 171.05
+ 12.27%). Animals under normoxic conditions and DEX
pretreatment showed low protein levels of IL-1𝛽 (DEX1: 111.95
+ 4.43%, DEX5: 107.86 + 5.15%, and DEX10: 112.44 + 5.43%).
4. Discussion
In the present study, we demonstrate that the 𝛼2-adren-
oceptor agonist dexmedetomidine leads to a decrease of
neurodegeneration and affects the level of oxidative stress
parameters and the proinflammatory cytokine IL-1𝛽 in a
model of neonatal hyperoxia-induced brain injury.
As shown previously oxygen toxicity leads to an increased
neurodegeneration in the immature brain [12, 16, 17, 38]. In
line with these studies here we indicate that an exposure of
six-day-old rats to a high oxygen concentration (FiO
2
80%)
over 24 h resulted in an increase of neurodegeneration to the
neonatal brain (Figures 1(a) and 1(b)).Moreover, we point out
a significant decrease of cell death in the developing rat brain
when infant rats were treated intraperitoneally with 1, 5, or
10 𝜇g/kg dexmedetomidine before exposure to high oxygen
conditions. These dosages are at/under the lower levels of
dexmedetomidine concentrations used in common adult rat
models of neuronal damage [39, 40] and the present data
are not intended to demonstrate the evidence of an effective
dose. However, our findings conform with different other
animal studies which examined the neuroprotective capac-
ity of dexmedetomidine [22–27]. Hyperoxia-exposed rats
revealed an up to 5-fold increase in cell degeneration within
the cortex and deep gray matter (Figure 1(b)), which has
been demonstrated in previous studies [17, 41]. Interestingly,
dexmedetomidine treatment showed a profound decrease of
degenerating cells in all analysed brain regions of rats exposed
to hyperoxia (Figure 1(b)). Dexmedetomidine alone induced
no oxidative stress, but at a relatively low concentration of
dexmedetomidine under normoxic conditions, a significant
increase in apoptosis in the cortex and the thalamus has
been shown. This result is controversial to other inventions
[31, 32, 42] and to the description of only protective and
no toxic effects [24, 25, 43]. In vitro it was shown by
Kuhmonen et al. [22] that dexmedetomidine is more effective
at lower doses and protects against delayed cell death. In an
ischemia-reperfusionmodel [39] antiapoptotic proteins were
upregulated and proapoptotic proteins are suppressed by
dexmedetomidine treatment. In the study by Li et al. there are
no changes in the expression of proapoptotic mediators in an
isoflurane-induced model of neuroapoptosis [40]. A proven
high blood pressure after the administration of high-dose
dexmedetomidine correlates with cerebral hypoperfusion
may be due to alpha-2-induced cerebral vasoconstriction
[44], so that this could contribute to apoptotic cell death
triggered by other cellular mechanisms. However, in our
study dexmedetomidine also led to negative effects in control
animals notably in the thalamus, and potential side effects
should be further considered in studies on protection of the
immature brain using dexmedetomidine.
The potency of dexmedetomidine in this model of oxy-
gen toxicity indicates that the 𝛼2-adrenoceptor agonist has
antioxidant activities. Of note, our hyperoxia model is pre-
dominantly based on free radical generation, as we previously
found an induction of different oxidative stress parameters
[12–15]. Therefore, we evaluated the effects on biochemical
markers of oxidative stress in the developing brain. The
concentrations of GSH and GSSG, the GSH/GSSG ratio, and
the MDA level were used as indicators of oxidative stress
and lipid breakdown. Hyperoxia-exposed P6 rats showed
significant decreased GSH and increased GSSG levels at
24 h of hyperoxia. In addition, a decrease in GSH/GSSG
ratio and an increase in MDA level in the developing
brain indicate neuronal damage due to oxidative stress,
but there was a modulation of the levels of all parameters




































































































































Figure 4: (a) Quantitative analysis of mRNA expression by real-time PCR showed a marked increase of IL-1𝛽 mRNA expression in the
brain of P6 rat pups that were kept for 24 h under hyperoxia (black bar), whereas dexmedetomidine treatment restores IL-1𝛽 upon control
level (hatched grey bars) depending on the dexmedetomidine concentration. Application of dexmedetomidine under room air (grey bars)
showed no significant regulation on IL-1𝛽 mRNA expression. (b) The analysis of IL-1𝛽 protein expression by western blot showed a similar
expression pattern. The protein expression of IL-1𝛽 is significantly increased after 24 h of hyperoxia and a single application of 5 or 10 𝜇g/kg
dexmedetomidine could restore the IL-1𝛽 protein expression almost up to control level. The densitometric data represent the ratio of the
pixel intensity of the IL-1𝛽 band to the corresponding 𝛽-actin band. Blots are representative of a series of three blots. Data are normalized
to levels of rat pups exposed to normoxia (CON = 100%, white bars). Bars represent mean + SEM; 𝑛 = 6 per group; ∗∗∗𝑃 < 0.001 versus
normoxia/control; #𝑃 < 0.05, ##𝑃 < 0.01, and ###𝑃 < 0.001 versus hyperoxia.
up to normoxia levels in hyperoxia-exposed neonatal rats
that received dexmedetomidine (Figures 2 and 3). These
observations suggest that dexmedetomidine seemingly has
an antioxidant activity against hyperoxia-induced oxidative
stress in the developing brain. In line with our findings there
are several studies that suggest an increased antioxidative
capacity of dexmedetomidine in the brain [24] and further
organs (reviewed by Tse et al. [45]).
This study indicates that dexmedetomidine significantly
decreases hyperoxia-induced IL-1𝛽 upregulation in the devel-
oping rat brain.These results illustrate the protective effect of
dexmedetomidine on neuroinflammation as shown before in
clinical and experimental studies [46, 47]. Dexmedetomidine
itself did not affect IL-1𝛽 levels, indicating that the 𝛼2-
adrenoceptor agonist only acts to normalize the induced
proinflammatory cytokine (Figure 4). Here, dexmedetomi-
dine appears to inhibit the production of inflammatory
mediators from multiple cell types, for example, astrocytes
and microglia [48, 49].
There are several limitations of this study pointing to areas
of future investigations. Dexmedetomidine was given only
once to the animals, while preterm infants receive an initial
loading dose and subsequent infusions [50] and the high
doses of dexmedetomidine studied here exceed those doses
recommended for clinical use; short term hyperoxia was
examined and preterm infants are often exposed to a longer
period of supraphysiological oxygen concentrations [51], and
we have not determined the plasma levels of dexmedeto-
midine. Further details of dexmedetomidine-induced side
effects remain to be elucidated.
To our knowledge this is the first report demonstrating
that dexmedetomidine mediates a decrease of neurodegen-
eration and oxidative stress and affects the expression of the
proinflammatory cytokine IL-1𝛽 in the hyperoxia-exposed
neonatal brain. Since oxidative stress and inflammation are
involved in dysfunction of the immature brain under high
oxygen conditions, 𝛼2-adrenoceptor activation seems to be
a potential neuroprotective treatment.
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5. Conclusion
The essential core of this work is the finding that dexmedeto-
midine prevents oxidative stress, inflammation, and cell
death in the neonatal brain under hyperoxic conditions.
Exposure to high oxygen in the developing brain of six-day-
old rat pups leads to increased oxidative stress-induced and
inflammatoryDNAdamage, as demonstrated by an increased
apoptotic rate, a reduction of the GSH/GSSG ratio, increased
lipid peroxidation, and increased IL-1𝛽 levels. Remarkably, a
single dose of dexmedetomidine has weakened or abolished
all these detrimental effects under hyperoxic conditions.
However, in this study dexmedetomidine also shows negative
effects in the control animals, and these potential side effects
should be taken into consideration in further studies on the
protection of the immature brain with dexmedetomidine.
Based on these data the hyperoxic model indicates
dexmedetomidine as a sedative in pediatric anesthesia and
a possible promising agent for neuroprotective strategies in
preterm infants.
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